Recently, Huzhou City, Zhejiang Province announced the list of the first batch of "South Taihu Lake Elite Program" innovation and entrepreneurship talent projects for 2023. The "Research and Industrialization of a New Type of IL-2 Fusion Protein Targeting PD-1 for the Treatment of Advanced Malignant Tumors" proposed by Novatim Immune Therapeutics (Zhejiang) Co., Ltd.(hereinafter referred to as "Novatim") was successfully selected as a leading entrepreneurial team project.
Dr. Wu Guoxiang, the founder and team leader of the company, introduced that this is a core product independently developed by Novatim from the very beginning. Its unique design concept has exerted the effect of the new generation agonist. Currently, in the same field, the research progress of this product is on par with that of Roche and is at the global leading position. It has obtained a number of international and domestic patents, and was also selected as a major research and development project of the Zhejiang Provincial Science and Technology Department last year. Currently, it is undergoing a formal clinical trial at the General Hospital of the People's Liberation Army of China. The preliminary clinical trial data has shown good safety and significant effectiveness.
Regarding Novatim
Novatim Immune Therapeutics (Zhejiang) Co., Ltd. was established in 2018. It is a biopharmaceutical technology enterprise specializing in the research and clinical application of innovative drugs for tumor immunotherapy. It wholly owns
Shanghai Tinova Immune Therapeutics Co., Ltd. Based on clinical needs and its focus on tumor immunotherapy, the company has established dual-function antibodies, bispecific ADC, CAR-T and other R&D platforms, and has developed nearly 10 FIC/BIC products.
In addition to the projects that have been officially included in the application process and have entered the formal clinical trial stage, the clinical trial application for the new generation CAR-T product targeting BCMA×CD19 CAR-T cell injection, which was independently developed, has also been approved by the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) in August this year. It will soon conduct I/IIa phase clinical research at Peking Union Medical College Hospital, focusing on patients with triple-line and relapsed/refractory multiple myeloma. Moreover, the world's first MET-EGFR dual-targeted ADC based on nanobody has entered the safety evaluation stage. The efficacy data in animal experiments is remarkable, and it is expected to obtain the approval for clinical trial applications in China and the United States in 2024.
